Citing the impact of the COVID-19 pandemic, Reata Pharmaceuticals (NASDAQ:RETA) has decided to halt the Phase 3 CATALYST
study evaluating bardoxolone methyl in patients with connective tissue
disease-associated pulmonary arterial hypertension (CTD-PAH). It is also
closing RANGER, the open-label extension study in PAH and pausing enrollment in the Phase 3 FALCON trial in autosomal dominant polycystic kidney disease.
The company does not anticipate any disruptions in the Phase 3 CARDINAL study in CKD or the MOXIe Part 2 trial evaluating omaveloxolone in patients with Friedreich’s ataxia.
Shares down 8% after hours.
https://seekingalpha.com/news/3556535-reata-stops-two-late-stage-studies-amid-covidminus-19-shares-down-8-after-hours
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.